←
Priya Sehgal MD MS MPH241 posts
Priya Sehgal MD MS MPH avatar

Priya Sehgal MD MS MPH

@phillyIBDdoc

IBD doc & Assistant Prof @TJUHospital | Passionate about #IBD & #weightwellness | IBD @PennGIHep | GI and MS @Columbiamed | IM & Med @DOMSinaiNYC

◷ Joined March 2012▧ 30 Photos and videos
Tauseef Ali MD, FACG AGAF FACP avatar
⟳ Priya Sehgal MD MS MPH retweeted
Tauseef Ali MD, FACG AGAF FACP@ibdtweets·Oct 24

🔥 HOT FROM ACG 2026 | NASHVILLE Five IBD Studies Worth a Closer Look! Another exciting ACG meeting, another opportunity to reflect on where IBD care is heading. From innovative drug delivery strategies to better symptom control, complex patient populations, and reproductive health, the science continues to evolve. For this special edition of IBD Library™, we invited Dr. @AsadurRahman87 , Medical Director of the IBD Center and Associate Program Director of the GI Fellowship at Cleveland Clinic Florida, to review five interesting studies presented at ACG 2026. 🔬 What's inside? 💉 Subcutaneous vs IV infliximab: Could route of administration influence outcomes in ileal Crohn's disease? 💊 Risankizumab AFFIRM trial: Another step toward an entirely subcutaneous treatment strategy. 🌙 Obefazimod in UC: Because bowel urgency and uninterrupted sleep matter to our patients. 🩺 JAK inhibitors in PSC associated IBD: Exploring options for a particularly challenging population. 👶 Fertility and IBD: Encouraging insights from the WIsDoM cohort on assisted reproductive technology. Innovation in IBD is no longer just about introducing another effective molecule. It is also about how we deliver treatment, what outcomes we prioritize, and how we address the needs of patients often underrepresented in clinical trials. Of course, conference abstracts generate important questions, but not necessarily immediate changes in practice. A special thank you to Dr. Asad ur Rahman for contributing his expertise to this edition of IBD Library™. 📖 Enjoy the review, and let us know: Which of these five studies caught your attention the most? #IBDLibrary #ACG2026 #CrohnsDisease #UlcerativeColitis #IBD #Gastroenterology #ClinicalResearch #MedicalEducation

Post attachment
Shrinivas Bishu avatar
⟳ Priya Sehgal MD MS MPH retweeted
Shrinivas Bishu@IBDimmunology·Jun 24

1/3: What #IBD meds work in ileal vs colonic CD? @AGA_CGH @AmerGastroAssn ✅Works in ileaIl: IL-23s and VDZ (!) 🟠Doesn’t work: JAKi (!) Caveats - but damn clever study. Rare 3 part post - look at all post for a simple methods (👇🏾) or skip to #3/3 cghjournal.org/article/S1542…

Cristina Tejera avatar
⟳ Priya Sehgal MD MS MPH retweeted
Cristina Tejera@cristinatejerap·Jun 3

Los agonistas del receptor de GLP-1 no solo bajan glucosa y peso, cada vez hay más evidencia de un efecto antiinflamatorio directo en múltiples órganos. La inflamación crónica es el hilo que conecta diabetes, enfermedad cardiovascular, hígado y cerebro. Revisión de esta semana en JCEM 👇 🔗 pubmed.ncbi.nlm.nih.gov/4221…

Post attachment
Parakkal Deepak MD, MS, FACG avatar
⟳ Priya Sehgal MD MS MPH retweeted
Parakkal Deepak MD, MS, FACG@P_DeepakIBDMD·May 26

Protocol for the ongoing consensus work on this topic in IBD with my co-PIs @amjohnsonMD @AndresYarur and a super team including @jalpa_devi @SamiSamaanMD @phillyIBDdoc Matt Vincent Shannon Coombs @MouhandMD and RAND/UCLA methodologist @EdBarnesMD Stay tuned for the actual 3 part survey output: Modulate Obesity and relateD metabolic complIcations For Yielding improvements in IBD outcomes (MODIFY-IBD): consensus on obesity and cardiometabolic comorbidities in inflammatory bowel disease using systematic reviews and the RAND/UCLA appropriateness m… @BMJ_Open bmjopen.bmj.com/content/16/5…

Jalpa Devi avatar
⟳ Priya Sehgal MD MS MPH retweeted
Jalpa Devi@jalpa_devi·May 27

⏳Our global patient survey on #Obesity, metabolic health, & #IBD is still OPEN. @UNMC_GIHEP @MayoClinic @washumedicine @CedarsSinai @ibdesis @saia_gi @P_DeepakIBDMD @ownyourcrohns @CrohnsColitisFn @AmerGastroAssn @AndresYarur @amjohnsonMD Survey link: tinyurl.com/37pufehu

SAIA@saia_giMay 11

Wash U in collaboration with UNMC, Mayo Clinic, Cedars Sinai and SAIA / IBDesis is conducting a survey to better understand patient experiences with weight management and metabolic health in IBD. Please take the following survey: wustl.az1.qualtrics.com/jfe/…. This survey is available across the globe for our patients who would like to have a voice on the topic! And always know that your lived experiences will guide future research, education, and discussion on the cutting-edge topic of #obesity & #IBD. If interested in participating in a PPI Day to further this research, please email @jalpa_devi and join us on Friday, June 5th from 11am to 1pm CDT. Thank you very much! #SAIA #IBDesis #CultureAndGI

Post attachment
Priya Sehgal MD MS MPH avatar
Priya Sehgal MD MS MPH@phillyIBDdoc·21 Dec 2025

Absolutely agree @ibdtweets

As gastroenterologists, we need to move past the outdated idea that IBD is only a disease of undernutrition. 📊 The evidence is clear: Obesity increases the risk of Crohn’s disease It is associated with more active disease and poorer outcomes It may reduce response to therapy And it increases surgical risk Visceral fat—especially mesenteric fat—is biologically active and can fuel intestinal inflammation. This has real implications for how we counsel patients, dose therapies, and design multidisciplinary care models. 💡 Obesity in IBD is not a failure—it’s a modifiable risk factor and an opportunity to improve outcomes. Proud to share this educational work through IBD Library™. @saia_gi @CrohnsColitisFn @CrohnsColitisUK @aboutIBD @getgutsycanada @gastrogirl @AmCollegeGastro @AmerGastroAssn linkedin.com/posts/ibd-libra…

American Gastroenterological Association (AGA) avatar
⟳ Priya Sehgal MD MS MPH retweeted
American Gastroenterological Association (AGA)@AmerGastroAssn·20 Nov 2025

Author @FrankIScottMD provides a great breakdown of our new living on managing moderate-to-severe Crohn’s disease. Clear, actionable insights for clinicians and patients alike. Looking forward to the full thread of recommendations. 👇

🚨AGA New Guideline Alert🚨 🔗gastro.org/clinical-guidance… ▶️AGA Living Guideline: Pharmacologic Management of Moderate-to-Severe Crohn’s Disease I’ll break down its 16 recommendations down over the next 10 tweets 🧵 👇 #AGA #GI #CD #IBD #MedTwitter 1/10

Post attachment
SAIA avatar
⟳ Priya Sehgal MD MS MPH retweeted
SAIA@saia_gi·14 Nov 2025

New Name, Growing Mission AND…🥁 Revamped Website & Socials 🙌🏽 Check out Strategic Alliance for Intercultural Advocacy in GI’s new website: saia-gi.org We are thrilled to share our website & social media reflect SAIA’s expanded focus to Culture & GI!

Post attachment
SAIA avatar
⟳ Priya Sehgal MD MS MPH retweeted
SAIA@saia_gi·8 Nov 2025

SAIA is proud to partner with Advances in Inflammatory Bowel Diseases (@ibdconference) 2025! Join us at the Walt Disney World Swan and Dolphin Resort in Orlando from Dec 8–10, 2025, for cutting-edge education, expert-led sessions & networking opportunities, with pre-conference workshops starting December 6-7. Register here: hmpglobalevents.com/aibd/rat… You can save $100 on registration with code 'SAIA' at checkout. Don’t miss this opportunity to be part of the year’s most impactful IBD conference 💥

Post attachment
SAIA avatar
⟳ Priya Sehgal MD MS MPH retweeted
SAIA@saia_gi·6 Oct 2025

This festive season, we’ve partnered with Crohn’s & Colitis Foundation on a FAB talk! Join Leana Patel moderating @ownyourcrohns, @phillyIBDdoc & @LivingWithUmeed as they discuss how to celebrate cultural festivals like Diwali with IBD! Tune in on Oct 9th on IG on saia_ibd / crohnscolitisfoundation!

Post attachment